Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_assertion type Assertion NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_head.
- NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_assertion description "[The study suggests that activating KRAS mutants is a particularly important independent predictive marker in mCRC patients treated with cetuximab plus chemotherapy, of which combing activating KRAS mutants and EGFR could help to identify the subgroup of patients who are most likely to respond to cetuximab plus chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_provenance.
- NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_assertion evidence source_evidence_literature NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_provenance.
- NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_assertion SIO_000772 20010090 NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_provenance.
- NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_assertion wasDerivedFrom gad-20130706 NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_provenance.
- NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_assertion wasGeneratedBy ECO_0000203 NP61162.RA4MWymq1lDFVMvC3psCizofkojjJf-or_Y711LxKuT88130_provenance.